



Chairman, Vice-Chairman and CMO in Scandion Oncology A/S buy Company shares

Scandion Oncology A/S ("Scandion Oncology" or "the Company") today announces that the Chairman, Vice Chairman and Chief Medical Officer of the Company have bought shares in Scandion Oncology. The shares have been acquired in the daily trading on Spotlight Stock Market.

Chairman of the Board Peter Høngaard Andersen has acquired 4,000 shares at a price of 10.85 SEK/share.

Vice-Chairman of the board Jørgen Bardenfleth has acquired 26,603 shares at a price of 11.74 SEK/share.

Chief Medical Officer Peter Michael Vestlev has acquired 13,792 shares at a price of 10.63 SEK/share.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

Scandion Oncology A/S is a biotechnology company that addresses and tackles one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company's leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.